INSUBCONTINENT EXCLUSIVE:
The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter
| Photo: Twitter @AjantaPharmaLtd1 min read Last Updated Jul 30 2024 | 11:12 PM IST
Ajanta Pharma on Tuesday said its consolidated profit
after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and
international markets.
The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal.
Revenue
from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said
in a regulatory filing.
The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter.
The
company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal.
Shares of Ajanta Pharma ended 3.99 per
cent up at Rs 2,524.35 apiece on the BSE.(Only the headline and picture of this report may have been reworked by the Business Standard
staff; the rest of the content is auto-generated from a syndicated feed.)First Published: Jul 30 2024 | 11:12 PMIST
